Jason Bock, CEO of CMTC, the joint venture between Resilience and MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of CAR-T therapies.

Don Wyatt, chief business officer for Highfield Biopharmaceuticals, discusses the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.

Jeremiah Robison, CEO of Cionic, discusses the company’s Neural sleeve, how functional electronical stimulation helps people with movement disorders walk, and how the use of adaptive algorithms continuously optimizes the stimulation it delivers.

Pete Carlson, CEO of Spectral AI, discusses the company’s AI-driven DeepView System for assessing burns, how it provides clinicians an objective and immediate assessment of a wound’s healing potential, and how it changes outcomes for patients.

New York City is not the first place that comes to mind when thinking of biotech clusters, but the Big Apple has been a growing center of biomedical innovation with its mix of academic research hospitals, finance, and growing number of biopharmaceutical companies. One place that’s seeking to serve as both a home to innovative companies and facilitate collaborations is Cure, which describes itself as a healthcare innovation campus. We spoke to Seema Kumar, CEO of Cure, about how it operates,...

Funding levels, drug launches, and R&D success rates all grew in 2023, according to a new report from the IQVIA Institute for Human Data Science. Global funding of biopharmaceutical research and development increased to $72 billion, up from $61 billion in 2022. M&A activity jumped to $140 billion from $78 billion during the same period. We spoke to Murray Aitken, executive director of the IQVIA Institute for Human Data Science, about its Global Trends in R&D 2024 report, what he’s...

Jon Isaacsohn, founder and CEO of CinRx, discusses the company’s portfolio approach, how its business model allows it to accelerate the development of needed medicines, and its efforts to develop new obesity therapies.

Brian Fiske, co-founder, chief scientific officer of Mythic Therapeutics, discusses the challenges that have held back the benefits of ADCs, how the company’s FateControl technology addresses those, and how it is thinking of building a pipeline of ADCs across indications.

Rachel Lenington, chief operating officer of Athira Pharma, discusses the case for targeting the HGF/MET neurotrophic system in neurodegenerative diseases, how its experimental therapy fosgonimeton works, and why its continuing to pursue the therapy despite earlier failures.

Mark Kotter, founder and CEO of Bit.Bio, discusses the company’s platform technology, its effort to develop cell therapies, and its growing offering of precision reprogramed human cells for drug development.

Erfane Awani, founder and CEO of Biomemory, discusses the use of DNA for data storage, how it works, and how quickly the technology can scale to where it competes with today’s data storage infrastructure.

Jacob Rubens, president of Quotient Therapeutics, discusses the company’s platform technology, how it uncovers genetic mutations at a cellular level, and its efforts to build a pipeline of therapies around the insights it gains.

Mahesh Karande, president and CEO of Omega Therapeutics, discusses his company’s pipeline of mRNA therapies, how they work, and its recently announced collaboration with Novo Nordisk to develop an epigenomic controller to treat obesity.

Larry Jasinski, CEO of ReWalk Robotics, discusses the company’s Personal Exoskeleton, how it works, and the impact it can have on the quality of life for someone with a spinal cord injury.

Navdeep Chandel, professor of medicine in the Division of Pulmonary and Critical Care and of biochemistry and molecular genetics at the Feinberg School of Medicine, about the state of our understanding of mitochondria, why drug developers are pursuing therapies to target mitochondria across a broad range of diseases, and the need for a concerted effort to conduct fundamental research to better understand the biology of this organelle.

Nadia Harhen, general manager of simulation and optimization for SandboxAQ, discusses the challenges of drug development it is seeking to address, how Sandbox AQ is leveraging quantum technologies, and why it is seeking to tackle an intractable set of diseases.

Charles Hugh-Jones, CEO of Volastra, discusses chromosomal instability in cancer cells, how the company is developing a pipeline of therapies to exploit this, and its expanding relationships with Big Pharma .

Adam Feuerstein, Polk award-winning journalist and senior biotech writer for STAT. discusses the biotech news that shaped 2023, the year’s best and worst CEOs, and what’s ahead in 2024.

Vik Bajaj, founder and CEO of Foresite Labs, discusses the changing data landscape around healthcare, the potential for technology to improve health outcomes, and what it takes for an entrepreneur to get his attention today.

Aron Knickerbocker, president and CEO of Aulos Bioscience, discusses the potential for IL-2 therapies to treat solid tumors, the limits of today’s IL-2 therapies, and the AI-based design behind its experimental IL-2 therapy in development.

Sujay Jadhav, CEO of Verana Health, discusses the potential for real-world data to improve outcomes for patients, how Verana is addressing challenges these data can present, and the areas of medicine on which it is focused.

Swaroop “Kittu” Kolluri, founder and managing director Neotribe Ventures, discusses the state of AI, the ability of technology to transform the healthcare environment, and Neotribe’s approach to investing.

Tom Miller, co-founder and CEO of Iambic Therapeutics, discusses the company’s AI platform, the insights Iambic gains from using a quantum mechanics-based approach to drug discovery, and its growing pipeline of cancer therapies.

John McDonough, executive chair and CEO of Sunbird Bio, discusses the company’s diagnostic test in development for Alzheimer’s disease, how it has the potential to impact treatments and outcomes for millions of patients with the condition, and how its merger with Glympse Bio is expected to push it into new markets.